Blood Cancer
Blood Cancer covers medicines used in the treatment of leukaemias, lymphomas and myeloma. The range includes tyrosine kinase inhibitors used in chronic myeloid leukaemia such as imatinib, nilotinib, ponatinib and asciminib; BTK and BCL-2 inhibitors such as ibrutinib and venetoclax; immunomodulatory agents such as lenalidomide; and cytotoxic and hypomethylating agents including hydroxyurea and azacitidine. Which of these is appropriate depends on the specific diagnosis, the stage of disease and, increasingly, on cytogenetic and molecular testing — so treatment follows investigation, and the determination belongs to a haematologist rather than to a product listing.
Many of these are available as generics produced by licensed manufacturers. Generic imatinib matches branded Gleevec, generic lenalidomide matches Revlimid, generic venetoclax matches Venclexta, and generic ibrutinib matches Imbruvica. In each case the generic contains the same active ingredient at the same strength as the brand; the difference is cost. For therapies often taken continuously for years, that difference is substantial.
Every medicine in this category is prescription-only and requires specialist supervision, including regular blood monitoring for most regimens. A valid prescription is required before any order can be dispensed, and our team can confirm availability and pricing for your destination. For wider context on how these treatments are used, visit our cancer medicines hub. Used as prescribed by a licensed medical professional.
